📊 CNTA Key Takeaways
Is Centessa Pharmaceuticals plc (CNTA) a Good Investment?
Centessa is a pre-commercial biotech company with zero revenue and quarterly operating cash burn of $72.2M, leaving only 2.6 months of cash runway at current burn rates. While the balance sheet structure is solid with $487.3M equity, the company faces an acute liquidity crisis requiring immediate capital raise or dramatic operational restructuring. Without demonstrated revenue generation or clear profitability path, fundamental viability is unsustainable.
Centessa Pharmaceuticals shows very weak current fundamentals, with revenue effectively disappearing year over year and operating losses remaining extremely large relative to its revenue base. While the balance sheet is not overleveraged and near-term liquidity appears strong, the company is still consuming substantial cash, so the core fundamental story depends on future pipeline execution rather than present operating strength.
Centessa Pharmaceuticals plc Key Strengths (CNTA)
- Strong equity base of $487.3M provides foundation for capital markets access and dilutive financing
- Conservative leverage with 0.23x debt-to-equity ratio maintains financial flexibility
- Improving loss trajectory with net income losses shrinking 16.2% year-over-year shows cost discipline
- Strong near-term liquidity with current and quick ratios of 10.57x
- Moderate leverage with debt-to-equity of 0.36x and positive equity base of $301.57M
- Net loss improved materially year over year, indicating some cost or expense normalization
CNTA Stock Risks: Centessa Pharmaceuticals plc Investment Risks
- Critical cash position: $62.4M cash against $72.2M quarterly burn rate equals ~2.6 months runway
- Zero revenue with no commercial-stage products and no demonstrated path to profitability
- Negative operating cash flow of -$72.2M per quarter indicates unsustainable development-stage burn rate
- Revenue declined 100% year over year, highlighting weak and potentially non-recurring commercial or collaboration income
- Profitability remains deeply negative, with operating margin of -928.1% and net margin of -875.8%
- Heavy cash burn with operating cash flow of -$138.01M and free cash flow of -$138.37M raises funding risk if losses persist
Key Metrics to Watch
- Monthly cash burn trajectory and remaining months of liquidity runway
- Capital raise announcements and access to funding markets at acceptable dilution
- Clinical trial advancement and regulatory milestones for pipeline candidates
- Quarterly operating cash burn and free cash flow trend
- Revenue durability and pipeline-driven milestone or product revenue conversion
Centessa Pharmaceuticals plc (CNTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.53x current ratio provides a solid financial cushion.
CNTA Profit Margin, ROE & Profitability Analysis
CNTA vs Healthcare Sector: How Centessa Pharmaceuticals plc Compares
How Centessa Pharmaceuticals plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Centessa Pharmaceuticals plc Stock Overvalued? CNTA Valuation Analysis 2026
Based on fundamental analysis, Centessa Pharmaceuticals plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Centessa Pharmaceuticals plc Balance Sheet: CNTA Debt, Cash & Liquidity
CNTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Centessa Pharmaceuticals plc's revenue has grown significantly by 119% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.06 indicates the company is currently unprofitable.
CNTA Revenue Growth, EPS Growth & YoY Performance
CNTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$26.1M | $-0.20 |
| Q3 2025 | N/A | -$42.6M | $-0.37 |
| Q2 2025 | N/A | -$43.8M | $-0.38 |
| Q1 2025 | N/A | -$26.1M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Centessa Pharmaceuticals plc Dividends, Buybacks & Capital Allocation
CNTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Centessa Pharmaceuticals plc (CIK: 0001847903)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNTA
What is the AI rating for CNTA?
Centessa Pharmaceuticals plc (CNTA) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNTA's key strengths?
Claude: Strong equity base of $487.3M provides foundation for capital markets access and dilutive financing. Conservative leverage with 0.23x debt-to-equity ratio maintains financial flexibility. ChatGPT: Strong near-term liquidity with current and quick ratios of 10.57x. Moderate leverage with debt-to-equity of 0.36x and positive equity base of $301.57M.
What are the risks of investing in CNTA?
Claude: Critical cash position: $62.4M cash against $72.2M quarterly burn rate equals ~2.6 months runway. Zero revenue with no commercial-stage products and no demonstrated path to profitability. ChatGPT: Revenue declined 100% year over year, highlighting weak and potentially non-recurring commercial or collaboration income. Profitability remains deeply negative, with operating margin of -928.1% and net margin of -875.8%.
What is CNTA's revenue and growth?
Centessa Pharmaceuticals plc reported revenue of $0.0.
Does CNTA pay dividends?
Centessa Pharmaceuticals plc does not currently pay dividends.
Where can I find CNTA SEC filings?
Official SEC filings for Centessa Pharmaceuticals plc (CIK: 0001847903) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNTA's EPS?
Centessa Pharmaceuticals plc has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CNTA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Centessa Pharmaceuticals plc has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CNTA stock overvalued or undervalued?
Valuation metrics for CNTA: ROE of -16.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CNTA's AI grade for 2026?
Our dual AI analysis gives Centessa Pharmaceuticals plc a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNTA's free cash flow?
Centessa Pharmaceuticals plc's operating cash flow is $-72.2M, with capital expenditures of $371.0K.
How does CNTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -16.3% (avg: 15%), current ratio 9.53 (avg: 2).